Molecular Partners AG (MOLN) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molecular Partners AG ("Molecular Partners" or the "Company") (NASDAQ: MOLN). Investors who purchased Molecular Partners securities are encouraged to obtain additional information and assist the investigation.


The investigation concerns whether Molecular Partners and certain of its officers and/or directors have violated federal securities laws.


On or around June 16, 2021, Molecular Partners conducted its U.S. initial public offering (“IPO”), offering 3 million American Depositary Shares (“ADS”) priced at $21.25 per ADS.  Then, on April 26, 2022, Molecular Partners issued a press release “announc[ing] that Amgen, its collaboration partner for MP0310 (AMG 506), has informed the Company of their decision to return global rights of MP0310 to Molecular Partners following a strategic pipeline review” and that “Molecular Partners is presently conducting a phase 1 study of MP0310 and will look to present full phase 1 data at a scientific conference when available.”  The press release further stated that “[u]nder the agreement with Amgen, following Phase 1 data, Amgen would have had the right to progress the program into later stage development, including into combination trials.”  On this news, Molecular Partners’ ADS price fell sharply during intraday trading on April 27, 2022.


If you are aware of any facts relating to this investigation or purchased Molecular Partners shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.